Series A Round

PAQ Therapeutics is a biotechnology company focused on developing KRAS degraders aimed at treating deadly cancers that currently lack effective treatment options. The company leverages its proprietary ATTEC platform to create novel therapies through autophagy-dependent degradation. With a mission to address significant unmet medical needs, PAQ Therapeutics aims to innovate cancer treatment by targeting specific genetic mutations and enhancing the body's natural degradation processes. The company is initially focused on a genetic neurodegenerative disorder, with plans to expand its platform to target a broader range of diseases.